Thynk Health and Riverain, pioneers in the healthcare artificial intelligence space, have announced a partnership between their platforms to fight lung cancer with the world's most advanced technologies. Combining all the latest technologies, including CAD, Machine Learning, clinical NLP, recurrent neural networks, and artificial intelligence, this partnership offers an unprecedented opportunity for lung cancer screening and pulmonary nodule management.
Thynk Health is the complete cancer screening and incidental finding management solution. Utilizing state-of-the-art artificial intelligence and deep learning algorithms, Thynk Health seamlessly integrates with EHRs and health systems to mine structured and unstructured data, organizing it in powerful, simple dashboards. With advanced automation and analytics, healthcare systems are empowering their cancer screening programs with actionable intelligence to be more effective and efficient.
"Radiologists are experiencing AI as an adjunctive tool, rather than the job-stealing technology previously warned by futuristic writers," said Joey Bargo, Thynk Health Co-Founder and Chief Product Officer. "This is evident in the ability to have a second set of eyes when looking for small or hilar region pulmonary nodules. When utilized in combination with advanced deep learning for language abstraction from reporting, AI technology is even more effective, allowing for radiologists to use traditional workflows, rather than archaic and cumbersome second workstation solutions."
Riverain Technologies is on a mission to revolutionize radiology by changing one in three delayed cardio-thoracic disease diagnoses to none in three. Using unique suppression technology, the ClearRead imaging interpretation solutions with Clear Visual Intelligence™ (CVI™) create an unobstructed view within the existing workflow so radiologists can focus on what matters to detect, precisely characterize, and report findings. Imaging interpretation with CVI™ moves radiologists beyond standard background-impaired imaging interpretation to allow focus on the actionable data to correctly and quickly detect cardio-thoracic diseases with newfound Certainty of Search™.
"Radiology is the gateway to finding, assessing, and reporting the course of many diseases, especially lung cancer, including evaluating the response to treatment. Yet the exploding volume and complexity of imaging interpretation, especially in chest CT scans, is creating a crisis for both patients and radiologists that must be addressed—now," said Steve Worrell, Riverain CEO. "This partnership will bring cutting-edge solutions to improve nodule detection and increase efficiencies in nodule management."
"The power of Thynk Health's AI-driven analytics abstracted from healthcare EHRs combined with Riverain's ClearRead suite significantly improves the ability to detect lung disease and changes the lives of patients, creating a comprehensive solution for lung cancer screening and pulmonary nodule management that offers healthcare systems a new level of patient care and growth and provides a new level of automation in the lung nodule diagnostic process," said Jeff Timbrook, Thynk Health CEO.
Lung Cancer continues to be the leading cause of cancer death among men and women, making up almost 25 percent of all cancer deaths (more than colon, breast, and prostate cancers combined). In 2022 the American Cancer Society estimates 236,740 new cases of lung cancer will be diagnosed, and 130,180 deaths from lung cancer will occur. Thynk Health and Riverain's partnership opens a new level of opportunity for healthcare systems to identify at-risk populations and diagnose and treat those populations when in early stages, significantly increasing survival rates. With advanced technology companies, healthcare systems, and communities partnering together, we can and we will win the fight against lung cancer.
About
The Thynk Health platform optimizes data-driven workflows and provides operational and clinical analytics for lung cancer screening programs and other quality initiatives. Thynk Health's Lung Module automatically identifies patients at risk for lung cancer, automates patient data and ACR submission, automates patient communications, automates tracking of incidental findings, engages providers, provides actionable LCS reports, and offers pulmonary nodule tracking. Thynk Health is EHR agnostic and integrates with existing hospital systems (EHR, DICOM, PACS, scheduling, and more). Learn more at thynkhealth.com
The Riverain ClearRead solution eliminates obstructions that often stand in the way of accurately and efficiently detecting disease in thoracic (lung) CT and XR images. Powered by machine learning and advanced modeling, our patented, FDA-cleared, and clinically proven software tools are deployed in the clinic or the cloud and are powered by the most advanced AI methods available to the medical imaging market. Learn more at riveraintech.com
Contact Information:
Thomas Croce
Marketing Manager
thomas.croce@thynkhealth.com
1-855-633-6963 x 711
Press Release Service by Newswire.com
Original Source: Thynk Health and Riverian Partner to Fight Lung Cancer With Advanced AI and Deep Learning Technologies
